| Management target | Revenue 2029 |
|---|
| Revenue growth | 20% YoY total; 32% YoY in US; 20% YoY in Europe. |
|---|---|
| Margins | EBITDA margin improved to 27% from 24% YoY. |
| Order book | 389 cumulative ANDA filings in the U.S. |
| Demand visibility | Increased demand from existing B2B customers. |
Growth
Revenue grew 20% YoY, EBITDA 34% YoY, and PAT 47% YoY. US market revenue rose 32% YoY.
Outlook
Ongoing expansion in complex injectables and RTU bags; technology transfer for global CDMO partnership expected by 2029.
Risks
Decline in India B2B sales due to lower Enoxaparin volume; negative growth in Other Core Markets (-28% YoY).
Last quarter's promises, checked
Delivered
- Guided 12-13% consol growth → delivered 20% (= BEAT)
- Guided US growth momentum → delivered 32% YoY (= BEAT)
- Guided EBITDA margin improvement → delivered 27% from 24% (= BEAT)
Partly delivered
- Guided steady Cenexi contribution → delivered positive EBITDA but group growth offset by India/Other Core declines (= PARTIAL)
Investor Presentation filed with NSE, NSE: GLAND. Summary written with AI assistance from the document.
Gland Pharma Ltd: key numbers
- Share price
- ₹2,917.20
- Market cap
- ₹48,137 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 42.6×Sector 50.4×
- Promoter holding
- 51.77%-0.06% QoQ
- FII holding
- 8.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Merger & Restructuring Worth ₹4.81 Cr
Gland Pharma is acquiring Gland Pharma USA Inc. for ₹4.81 Crore to streamline its corporate structure by making it a direct wholly-owned subsidiary.
- Value
- ₹4.81 Cr
Gland Pharma Acquisition Worth ₹4.76 Cr
Gland Pharma approved acquiring its step-down subsidiary, Gland Pharma USA Inc., from another wholly-owned subsidiary to streamline corporate structure. The transaction costs USD 5,01,208.
- Value
- ₹4.76 Cr
- Execution
- By October 31, 2026
Gland Pharma Employee Stock Options
Gland Pharma Limited granted 5,90,249 employee stock options to 124 employees under its ESOP 2025 scheme. These options are subject to specified vesting schedules and pricing.
Gland Pharma Legal & Regulatory
Gland Pharma paid fines totaling ₹1.40 Lakh to NSE and BSE for a technical regulatory non-compliance breach. The company has since ensured compliance with shareholder approval.
- Value
- ₹0.14 Cr
Gland Pharma Promoter Selling
Fosun Pharma Industrial Pte. Ltd., a promoter, sold 98,97,000 Gland Pharma shares in the open market. Its stake fell from 51.76% to 45.76%.
Gland Pharma Investor Presentation: Key Takeaways
Gland Pharma reported strong Q1FY27 results with 20% revenue growth and 47% PAT growth. Management highlighted a major strategic CDMO contract and raised long-term CAGR outlook to 20% following recent business wins.
- Call
- Guides 15% growth